A5087898022- Head and Neck Cancer Studies
- Head and Neck Surgical Oncology
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Ferroelectric and Piezoelectric Materials
- Cancer-related molecular mechanisms research
- Brain Metastases and Treatment
- Viral-associated cancers and disorders
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Salivary Gland Tumors Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Acoustic Wave Resonator Technologies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Oral health in cancer treatment
- Medical Imaging Techniques and Applications
- Ear and Head Tumors
- Microwave Dielectric Ceramics Synthesis
- Liver physiology and pathology
- Multiferroics and related materials
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
Harbin Medical University
2023-2025
Sun Yat-sen University Cancer Center
2016-2025
Jingdezhen Ceramic Institute
2023-2025
Sun Yat-sen University
2016-2025
Sichuan University
2018-2025
West China Hospital of Sichuan University
2018-2025
Technology and Engineering Center for Space Utilization
2024-2025
Chinese Academy of Sciences
2024-2025
Shandong Center for Disease Control and Prevention
2025
University of Chicago
2025
This study aimed to establish an effective prognostic nomogram with or without plasma Epstein-Barr virus DNA (EBV DNA) for nondisseminated nasopharyngeal carcinoma (NPC). The was based on a retrospective of 4630 patients who underwent radiotherapy chemotherapy at Sun Yat-sen University Cancer Center from 2007 2009. predictive accuracy and discriminative ability the were determined by concordance index (C-index) calibration curve compared EBV current staging system. results validated using...
Abstract BACKGROUND: The aim of this phase 2 study was to determine the long‐term local control, survival, and late toxicities among patients with locally advanced nasopharyngeal carcinoma (NPC) treated intensity‐modulated radiotherapy (IMRT) simultaneous modulated accelerated radiation therapy (SMART) boost technique concurrent chemotherapy. METHODS: Eighty‐one pathologically diagnosed NPC were enrolled in study. IMRT delivered SMART at prescribed doses 68 grays (Gy)/30 fraction nasopharynx...
To evaluate which patients with nasopharyngeal carcinoma (NPC) obtained the greatest benefits from detection of distant metastasis [(18)F]fluorodeoxyglucose positron emission tomography and computed (PET/CT) combined plasma Epstein-Barr virus (EBV) DNA levels.Consecutive NPC were prospectively enrolled. PET/CT, conventional work-up (CWU), quantification EBV performed before treatment. The accuracy these strategies for metastases was assessed. costs diagnostic compared.Eighty-six (14.8%) 583...
BACKGROUND Circulating Epstein‐Barr virus DNA is a predictor of disease recurrence in patients with nasopharyngeal carcinoma. human papillomavirus (HPV) has been detected the sera some HPV‐positive squamous cell carcinoma oropharynx (OPC). The goal current study was to determine whether pretreatment serum HPV useful biomarker for OPC. METHODS included newly diagnosed, previously untreated Tumor status determined by polymerase chain reaction; using real‐time reaction. Differences clinical...
Purpose To investigate for a prognostic index (PI) to personalize recommendations salvage intensity-modulated radiotherapy (IMRT) in patients with locally recurrent nasopharyngeal carcinoma (lrNPC). Methods Patients lrNPC from two academic institutions (Sun Yat-Sen University Cancer Center [SYSUCC-A; n = 251 (training cohort)] and National Centre Singapore [NCCS; 114] SYSUCC-B [n 193 (validation cohorts)]) underwent treatment IMRT 2001 2015. Primary secondary clinical end points were overall...
GEM20110714 (ClinicalTrials.gov identifier: NCT01528618), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement with gemcitabine plus cisplatin (GP) versus fluorouracil (FP; hazard ratio, 0.55; 95% CI, 0.44 to 0.68;
To investigate the feasibility of synthesizing computed tomography (CT) images from magnetic resonance (MR) using generative adversarial networks (GANs) for nasopharyngeal carcinoma (NPC) intensity-modulated radiotherapy (IMRT) planning.Conventional T1-weighted MR and CT were acquired 173 NPC patients. The 28 patients randomly chosen as independent tested set. remaining used to build a conditional GAN (cGAN) cycle-consistency (cycleGAN). A U-net was generator in cGAN, whereas residual-Unet...
Radioresistance is the primary cause of nasopharyngeal carcinoma (NPC) treatment failure. Previous studies have focused on deficits in cellular apoptosis as a mechanism for radioresistance; however, additional potential death modes involved modulating radiosensitivity NPC not been explored.Pyroptosis was assessed by phase-contrast imaging, LDH release assays, live cell and Western blotting. In vitro vivo assays were used to investigate function gasdermin E (GSDME) ovarian tumor family...
Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear.To determine whether paclitaxel, cisplatin, and capecitabine (TPC) vs cisplatin fluorouracil (PF) prior stage IVA IVB carcinoma.This randomized, open-label, phase 3 clinical trial recruited 238 at 4 hospitals in China from October 20, 2016, August 29, 2019. Patients were 18 65 years...
Cumulative doses of 200 mg/m2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority a two-cycle 100 DDP regimen over three-cycle patients with low-risk LA-NPC pretreatment Epstein-Barr virus DNA levels < 4,000 copies/mL.Eligible randomly assigned 1:1 receive two cycles or three...
Induction or adjuvant chemotherapy with concurrent chemoradiotherapy (CCRT) are first-line treatment options for of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Adjuvant platinum regimens are, however, poorly tolerated, highlighting the unmet need an efficacious, tolerable regimen.